1 / 52

This lecture is sponsored by a grant from the Delta Dental of Iowa Foundation IDA Annual Conference Guest Lecture Serie

This lecture is sponsored by a grant from the Delta Dental of Iowa Foundation IDA Annual Conference Guest Lecture Series . Diabetes Essentials 2011. Richard LeBlond, MD, MACP Chief Quality Officer Professor, Internal Medicine University of Iowa Health Care. Learning Objectives.

jane
Télécharger la présentation

This lecture is sponsored by a grant from the Delta Dental of Iowa Foundation IDA Annual Conference Guest Lecture Serie

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. This lecture is sponsored by a grant from the Delta Dental of Iowa Foundation IDA Annual Conference Guest Lecture Series.

  2. Diabetes Essentials 2011 Richard LeBlond, MD, MACP Chief Quality Officer Professor, Internal Medicine University of Iowa Health Care

  3. Learning Objectives • Appreciate the challenge of diabetes from the patient’s perspective • Differentiate type 1 from type 2 • Understand insulin action • Understand complications of diabetes • Know the major classes of medications • Know the side effects of each class • Recognize hypoglycemia as a serious complication arising during dental care

  4. Diabetes Incidence in Childhood

  5. What is Diabetes?Insufficient insulin activity • Defined by the blood glucose level • The definition is arbitrary • Fasting glucose >125 mg/dL • 2 hour post meal glucose > 200 mg/dL • Any glucose > 200 mg/dL • Glycohemoglobin > 6.5% • Two predominant causes • Decreased insulin levels: type 1 • Resistance to insulin action: type 2

  6. Insulin • Insulin is produced by the beta cells in the islets of the pancreas • Small amounts of insulin are necessary to sustain life • Insulin is necessary for the metabolism of carbohydrates • Insulin acts predominantly on three tissues • Fat cells: take up glucose, convert to fatty acids, and store energy as triglycerides • Muscle cells: take up glucose and store as glycogen • Liver: take up glucose and store as glycogen; stop gluconeogenesis (making glucose from amino acids)

  7. Causes of Diabetes • Type 1: destruction of pancreatic islet cells • Autoimmune, usually childhood onset; genetic predisposition; probable viral trigger • Non-immune destruction: acute and chronic pancreatitis; hemochromatosis • Type 2: resistance to insulin action • Genetic factors • Obesity: decreased adipocyte responsiveness to insulin • Maturity Onset Diabetes of the Young (MODY): abnormal insulin signaling • Corticosteroids & stress hormones: cortisol (Cushing syndrome), growth hormone (acromegaly), epinephrine

  8. Type 1 DiabetesAbsolute Insulin Deficiency • Incompatible with life • Ketoacidosis without insulin • Exogenous insulin is the only treatment • Usually young and thin • No family history of diabetes • Common causes of death: • Ketoacidosis • Hypoglycemia • Kidney failure • Heart attack

  9. Type 2 DiabetesResistance to Insulin Action • Gradual onset and progression over years • Strong family history • Usually overweight or obese • Diagnosis in middle age (this is changing rapidly) • Many treatment options • Long survival even without treatment • Common causes of death: • Heart attack • Kidney failure

  10. Hypoglycemia • Blood sugar <50 mg/dL associated with brain dysfunction and can lead to death • Type 1 diabetics more susceptible • Medication overdose: insulin or sulfonylureas • Taking medication but not eating, or unable to eat • Taking medication and exercising strenuously • Symptoms • Autonomic response: shaky, sweating, hunger, agitation • Neuroglycopenic symptoms: confusion, lethargy, coma • Treatment: oral glucose, glucagon, iv glucose

  11. Hypoglycemia Unawareness • Occurs in type1 diabetics with frequent episodes of mild-moderate hypoglycemia • Blunted autonomic reflex responses to hypoglycemia • Only neuroglycopenic symptoms occur • Inability to think clearly (judgment is the first to go) leads to inappropriate, ineffective or no response • Greatly increased risk of death • Absolute avoidance of hypoglycemia for several months restores responsiveness

  12. Long Term Complications of DiabetesMicrovascular • Damage to the small arterioles becomes manifest in specific organs • Retinopathy: leading cause of blindness in US • Neuropathy: • loss of protective sensation in the feet and legs • Autonomic neuropathy: loss of cardiovascular and gastrointestinal autoregulation • Nephropathy: loss of functional nephron mass leading to kidney failure. Leading cause for ESRD and dialysis in the US • Microvascular complications are slowed or prevented by tight glucose control (Hb A1c < 6.5%)

  13. Long Term Complications of DiabetesMacrovascular • Accelerated atherosclerosis of the major arteries • Myocardial infarction: heart attack risk is the same as someone who has had an MI • Stroke: strong cofactor with hypertension • Peripheral vascular disease: strong cofactors are smoking and male gender • Tight glucose control (Hb A1c < 6.5%) does not have an advantage over good control (Hb A1c 7.5%) • Prevention strategy is to manage all risk factors: smoking, blood pressure (< 130/80), LDL-C (<70 mg/dL), exercise, weight loss

  14. Other Complications of Diabetes • Increase with blood sugars > 200 mg/dL • Mucocutaneous fungal infections: • Oral candidiasis • Vulvovaginal candidiasis • Periodontal disease • Poor wound healing • Wound infections • Urinary tract infections • Skin and soft tissue infections

  15. MANAGEMENT:Goals, Objectives &Tools • Goals: • the long term outcomes desired by the patient and the physician • Objectives: • the objective easily measurable way points marking progress towards the goals • Tools: • techniques, medications and other interventions used to achieve the objectives

  16. Long-term Goals 1. Life Goals • Family • Employment • Avocations 2. Medical Goals -Prevent microvascular disease -Decrease risk for macrovascular disease -Prevent hypoglycemic complications -Prevent the 5 D’s: death, disability, depression, dependency, destitution

  17. Long-term Objectives • Meaningful clinically • Meaningful to the patient • Objective • Measurable • Easily assessed by the patient • Transparent: easily interpreted

  18. Long-term Objectives • Normal function • No severe hypoglycemia • Hemoglobin A1c ≤ 7% • Maximum glucose <180 mg/dL checked 1 ½ to 2 hours after meals

  19. Long-term Objectives Prioritized • Normal function • No severe hypoglycemia • Hemoglobin A1c ≤ 7% • Maximum glucose <180 mg/dL checked 1 ½ to 2 hours after meals

  20. Tools • Education • Diet • Glucose monitoring • Exercise • Medications • Devices • Doctors: exams, other labs

  21. Tools Priority • Education • Diet • Glucose monitoring • Exercise • Medications • Devices • Doctors: exams, other labs

  22. Non Blood Sugar ObjectivesGaede P, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91 • BP < 130/80, lower is better: whatever it takes • Lipid control, TC, LDL-C, TG: statin • Diet: -total calories -low carbohydrate diet 4. Obesity -diet, drugs, surgery -progressive weight loss, weight target • Exercise: rehab, PT, 10,000 steps daily • Preventive Care: foot exam, immunizations, etc • Manage albuminuria & CKD: ACE-I, BP control • Mood, depression impairs management: ? SSRI

  23. Modern Insulin Management:All Type 1 and some Type 2 patients • Optimal insulins are synthetic & humanized • Basal insulin: very long acting • Given daily, often in the evening • Humanized long acting: glargine (Lantus®), detemir • Prandial insulin: very short acting insulins • Given with meals • Humanized very short acting: lispro (Humalog®), aspart, glulisine • Correction dose insulin • Lower glucose elevated above premeal target level • Given 30-60 minutes before meals • Humanized very short acting insulins

  24. Other Drugs for Type 1 and Type 2 • Glucagon: • antagonizes insulin effect for rapid reversal of hypoglycemia • Older Insulins: suboptimal treatment choices, but less expensive • Animal derived intermediate acting: NPH, Lente • Animal derived short acting: Regular • Fixed dose mixtures: 70/30 (70% NPH, 30% Regular)

  25. Drugs To Treat Type 2 Diabetes • Injectable: • Insulin • Incretin (GLP-1) agonists • Oral • Metformin • Sulfoylureas • TZDs: thiazolidinediones • DPP4 inhibitors • Gut absorption blockers • Meglitinides

  26. Metformin • Drug of first choice for type 2 diabetes • Generic and low cost • Twice daily dosing • Increases insulin effect • Decrease liver glucose production • Increases peripheral glucose uptake • Does not cause hypoglycemia • Does not cause weight gain • Side effects: • Diarrhea • Lactic acidosis, rare

  27. Sulfonylureas • Older agents • Inexpensive • Long acting • Stimulate insulin release by beta cells • Side effects • Weight gain • hypoglycemia

  28. Meglitinides • Repaglinide, neglitinide • Increase insulin release by a different mechanism than sulfonylureas • Fast and short acting • Taken before meals to lower post prandial glucose rise • Side effects • hypoglycemia

  29. Incretin (GLP-1) mimetics • Two available: exenatide (Byetta®) • Injectable • Once daily • Expensive • Used alone rarely causes hypoglycemia • Does not cause weight gain • Side effects • Nausea is very common (> 40%) • Slowed gastric emptying

  30. DPP4 Inhibitors • Oral once or twice a day • Two drugs available: sitagliptin, saxagliptin • Newer, expensive, second line • Inhibit breakdown of incretins • Do not cause weight gain • Do not cause hypoglycemia • Side effects: few

  31. Thiazolidinediones • Oral, intermediate duration, once or twice a day • Increase sensitivity to insulin action • Two drugs in class: pioglitazone (Actos®), rosiglitasone (Avandia®) • Do not cause hypoglycemia • Cause weight gain • Side effects • Fluid retention and heart failure • Possible increased risk of MI

  32. Second Line Drugs • Alphaglucosidase inhibitors (acarbose and others) • Blocks carbohydrate digestion • Slows glucose absorption • Used in combination with metformin • Flatulence and diarrhea • Lipase inhibitors: orlistat (Xenical®) • Block fat digestion • Diarrhea

  33. Hypoglycemia:Which patient should concern you? • Type 1 on insulin • Not obese • History of hypoglycemia (high risk for hypoglycemia unawareness) • Acute oral issues impairing chewing or swallowing • Sedation • Longer procedures

  34. What signs should concern you? • Anxiety • Sweating • Uncooperativeness • Confusion • Sedation • Decreased pain response

  35. What Should You Do? • Immediately stop the procedure • If aware and cooperative, give something to eat • If possible have the patient check their glucose • For unresponsive patient: • Call 911 • Give glucagon if available • 50% dextrose intravenously • Do not put food in the mouth

  36. Learning Objectives • Appreciate the challenge of diabetes from the patient’s perspective • Differentiate type 1 from type 2 • Understand insulin action • Understand complications of diabetes • Recognize major classes of medications • Recognize side effects of each class • Recognize potential complications affecting dental care

  37. Diabetes Essentials 2011 QUESTIONS? Richard LeBlond, MD, MACP Chief Quality Officer Professor, Internal Medicine University of Iowa Health Care

  38. Complications of Diabetes: Ketoacidosis • Insufficient insulin • Glucose cannot enter muscle so glucose levels rise • Absent insulin signal to liver and fat • Fat releases triglycerides which are metabolized in muscle to ketoacids • Liver starts making glucose further increasing glucose • Osmotic diuresis leads to volume depletion • Ketoacids produces metabolic acidosis aggravated by volume depletion • Death from severe acidosis and hypotension

  39. Treatment of Ketoacidosis • Replace volume deficits with normal saline, usually several liters • Intravenous insulin drip • Replace electrolytes, particularly KCl • Continue insulin drip even when glucose becomes normal • Transition to subcutaneous insulin after all metabolic abnormalities are corrected

  40. Care at Home Locus of Care Personal Organism Social Person

  41. Shared Responsibility: Who is responsible and accountable for what • Ask the patient “whose problem is this?” • Repeat and wait until the patient (not the spouse, family member, etc.) acknowledges their responsibility • The outcome is most dependent upon the patient’s not the doctor’s activities • The patient will receive the benefits or consequences of the decisions and actions

  42. What should we conclude? • Benefit is achieved in reducing A1c from > 9.0 to <7.0% • No clear benefit with lowering A1c to ≤ 6.5% • A1c is a continuous not dichotomous variable • One studies “intensive” is the next study’s control • Recent studies show increased harm, including death, with more intensive therapy • Severe hypoglycemia increased with intensive therapy • Achieving tight control is resource intensive (time, drugs, supplies, emotional)

  43. In the absence of clearly-defined goals we become strangely loyal to performing daily trivia until ultimately we become enslaved by it. -Robert Heinlein

  44. Symptoms of Diabetes • Weight Loss • Increased Appetite • Increased Urination • Large urine volumes • Frequent voiding at night • Visual Changes: blurring • Fatigue, decreased energy

More Related